Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database

• Egile Nagusiak: Chih‐Lin Chiang (Egilea), Madoka Chinen (Egilea), Mehmet Daskiran (Egilea), Akihide Wakamatsu (Egilea), Ibrahim Turkoz (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2024-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Aim Real‐world data (RWD) for paliperidone palmitate (PP) three‐monthly (PP3M) is lacking based on Japan label requirements. This study evaluated the clinical effectiveness of PP3M versus PP once‐monthly (PP1M) in patients with schizophrenia administered according to Japan label requirement...